ERIKA MULLEN: Open Payments
NPI 1306008065 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$363 in 18 payments from 7 companies in 2025. Trend: 2023 $250 · 2024 $444 · 2025 $363
Food & beverage: $363
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 3 | $76 |
| Novartis Pharmaceuticals Corporation | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| AstraZeneca Pharmaceuticals LP | 3 | $51 |
| GlaxoSmithKline, LLC. | 2 | $50 |
| Amgen Inc. | 3 | $43 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
Products named: DUPIXENT, TEZSPIRE, TRELEGY ELLIPTA, Rhapsido, NEFFY.
Industry payments across TX — which companies pay providers there.
